Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226687 | 1.00 | KDM4E (0.47) | KDM4ESIRT6KMT2AALDH1A1MAPT | |
| SCHEMBL22684135 | 0.80 | ALDH1A1 (0.48) | KDM4EKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL2229043 | 0.80 | ADAMTS5 (0.42) | KMT2AMEN1ADAMTS5ADAMTS4CCR1 | |
| SCHEMBL12479736 | 0.78 | SIRT6 (0.72) | KDM4ESIRT6KMT2AALDH1A1MAPT | |
| SCHEMBL12479741 | 0.78 | SIRT6 (0.72) | KDM4ESIRT6KMT2AALDH1A1MAPT | |
| SCHEMBL5396736 | 0.76 | ALDH1A1 (0.52) | KDM4EKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL11350437 | 0.73 | NPSR1 (0.52) | SIRT6KMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL20139830 | 0.72 | HTT (0.45) | KDM4EKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL1675837 | 0.72 | HTT (0.53) | KDM4EKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL30087222 | 0.72 | HTT (0.53) | KDM4EKMT2AALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975250-B2 | 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases | SANOFI (FR) | 2015-03-10 | — | — | US | disclosed |
| EP-2521726-B1 | 5-OXO-5,8-DIHYDROPYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CAMKII KINASES INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | SANOFI SA (FR) | 2013-12-18 | — | — | EP | disclosed |
| EP-2521726-A1 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI (FR) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI (FR) | 2012-11-01 | — | — | US | disclosed |
| WO-2011086306-A9 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011086306-A1 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | CAMKK1, CAMKK2, CAMK1 | KDM4E 2091/4885SIRT6 1832/4885KMT2A 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.